Läkemedel
Cornellstudie kopplar GLP-1-läkemedel som Ozempic och Wegovy till lägre hushållsutgifter för mat
Rapporterad av AI Bild genererad av AI Faktagranskad
Hushåll som börjar med aptitdämpande GLP-1-läkemedel som Ozempic och Wegovy minskar matkostnaderna inom månader, inklusive i livsmedelsbutiker och begränsade servicerestauranger, enligt ny forskning från Cornell University baserat på länkade enkätsvar och transaktionsdata.
Australiska forskare har rapporterat positiva resultat från en fas II klinisk prövning av ett nytt kolhydratbaserat läkemedel för behandling av sepsis. Prövningen, som involverade 180 patienter i Kina, visade läkemedlets förmåga att minska tillståndets svårighetsgrad. Denna utveckling ger hopp om den första riktade terapin mot en ledande dödsorsak globalt.
Rapporterad av AI
A Delhi High Court verdict on January 12 has allowed Indian pharma company Zydus Lifesciences to manufacture and sell a biosimilar version of Bristol Myers-Squibb's cancer drug Nivolumab. This ruling could pave the way for more affordable immunotherapy treatments for cancer patients in India. Nivolumab is effective against various cancers, with its patent set to expire in May 2026.
Egypt's Minister of Health and Population, Khaled Abdel Ghaffar, held an expanded meeting on Monday with representatives of relevant state bodies to discuss ways to support pharmaceutical manufacturers and draft a comprehensive policy framework for boosting local production and localizing biopharmaceutical and biological products.
Rapporterad av AI
Daiichi Sankyo announced it will begin over-the-counter sales of the emergency contraceptive Norlevo on February 2, marking the first time such a pill is available without a prescription in Japan. The pill must be taken in the presence of a trained pharmacist for safety reasons.
Chile's Public Health Institute warned of two new risks linked to leuprorelina-containing drugs, used for advanced prostate cancer treatment. These include liver issues like fatty liver and severe skin reactions that can be fatal. The review drew from international evidence, with no local cases reported in the past 12 years.
Rapporterad av AI
The RD Saúde group, owner of the Raia and Drogasil chains, obtained a license to produce and sell over 20 molecules of over-the-counter medicines starting in 2026. The initiative was announced during the RD Day in São Paulo. The products will be launched under the Bwell brand.
Egypt and Kazakhstan discuss pharmaceutical technology transfer and health cooperation
13 januari 2026 06:14SciNeuro and Novartis sign $1.7 billion Alzheimer's drug deal
12 januari 2026 01:52India and Egypt strengthen pharmaceutical ties through high-level delegation visit
10 januari 2026 18:59Egypt backs African Medicines Agency, pushes for continent-wide regulatory integration
9 januari 2026 09:41FNE measures in celecoxib market generate over US$ 346 million in savings
18 december 2025 19:32Takeda's AI-developed psoriasis pill succeeds in trials
13 december 2025 06:15Public enterprises ministry prioritises support for pharmaceutical affiliates: El-Shimy
12 december 2025 12:54Alzheimer's drug trials adopt cancer's multi-target approach
10 december 2025 17:32Egypt and Belarus discuss expanded health cooperation and joint production
7 december 2025 13:42Oral β2-agonist targeting muscle metabolism shows promise for type 2 diabetes and obesity